SANUWAVE Health, Inc. (SNWV) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of SANUWAVE Health, Inc. $11.03, price $4.71, upside +134.3%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SANUWAVE Health, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.5250 – $75.15 · fair‑value band $6.87 – $17.33 · the $4.71 price screens below the $11.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow SANUWAVE Health, Inc. Common Stock in your weekly email
Every Wednesday you see whether SANUWAVE Health, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.
Show more
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Stock analysis
SANUWAVE Health, Inc. Common Stock (SNWV) currently trades at $4.71, while our model-based Fair Value estimate is $11.03, implying the stock looks roughly 57.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $63.83 per share, and 20 of the 24 models we run sit above the $4.71 price.
Bear case: the Economic Profit group reads lowest at $1.39, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $6.87 (bear) to $17.33 (bull), the price of $4.71 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SANUWAVE Health, Inc. Common Stock reported revenue of $44.1M in FY2025 versus $13.0M in FY2021, a compound +35.6%/yr. Reported net income was $11.8M in FY2025.
Key figures
Market cap $77.5M · P/E ratio 4.9 · P/S ratio 1.31 · EPS (TTM) $0.9600 · Net margin 26.8% · Return on assets (EBIT) −18.4% · Operating margin −11.7% · Revenue (TTM) $44.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 88% below its 52-week high and 18% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 134%, SNWV screens cheaper than that median.
Fair Value models
Bear $6.87Fair Value $11.03Bull $17.33
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.7049 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+35.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.1%
Start year 2020 (pandemic). Over 10 years: +46.5% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−444.0% (2020) → 11.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +22.4% a year for the price.
Compare SANUWAVE Health, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+134% · Top 25%
Profitability
Return on assets9% · Top 25%
Net margin (TTM)37% · Top 25%
Operating margin (TTM)−12% · Below median
Growth and dividend
Revenue growth3% · Below median
Balance sheet
Debt / equity10.08× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (TTM)4.9× · Cheapest 25%
P/B47.85× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SANUWAVE Health, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/SNWV
Frequently asked questions
Is SANUWAVE Health, Inc. (SNWV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $11.03 versus a price of $4.71, about +134% upside (undervalued).
What is the fair value of SNWV?
Our model-based fair value for SANUWAVE Health, Inc. Common Stock is $11.03 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.71.
What is the quality score of SNWV?
SANUWAVE Health, Inc. Common Stock has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SANUWAVE Health, Inc. (SNWV)?
Our model-based price target is the fair value of $11.03 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $6.87, optimistic scenario $17.33. It is a calculation from audited fundamentals, not an analyst target.
What is the SANUWAVE Health, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $11.03, about +134% upside versus a price of $4.71 (undervalued). Cautious scenario $6.87, optimistic scenario $17.33. The calculation is refreshed regularly with new filings.
What is the revenue of SANUWAVE Health, Inc. (SNWV)?
SANUWAVE Health, Inc. Common Stock reported trailing-twelve-month revenue of about $44.3M (latest available figure, as of Sep 23, 2026).
What growth is priced into SANUWAVE Health, Inc. (SNWV)?
For today's price to be fair in a discounted-cash-flow model, SANUWAVE Health, Inc. Common Stock would have to grow free cash flow by +25.3 % per year for five years (discount rate 13.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +61.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of SNWV use?
Our models discount SANUWAVE Health, Inc. Common Stock at 13.8 %: a base by market capitalisation (micro), damped by beta 1.35, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SANUWAVE Health, Inc. Common Stock that is +25.3 % per year a year over ten years, using the same discount rate (13.8 %) and the same formula as our fair value.
How much growth has SANUWAVE Health, Inc. (SNWV) delivered so far?
Over the past 5 years revenue at SANUWAVE Health, Inc. Common Stock grew +61.1 % a year. The price currently implies +25.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SANUWAVE Health, Inc. (SNWV) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into SANUWAVE Health, Inc. Common Stock (+25.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SANUWAVE Health, Inc. (SNWV)?
The free-cash-flow yield on the price is 4.53 %: that much free cash flow SANUWAVE Health, Inc. Common Stock produces per unit of market value. When it exceeds the discount rate of our models (13.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SANUWAVE Health, Inc. (SNWV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SANUWAVE Health, Inc. Common Stock it is $11.03 per share (as of Sep 23, 2026), against a price of $4.71. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is SANUWAVE Health, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SNWV trades below its calculated fair value: price $4.71, fair value $11.03, a gap of about +134% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SNWV?
No. The price is what the market pays today ($4.71); the fair value is what the company's own numbers justify ($11.03). For SANUWAVE Health, Inc. Common Stock the two are $6.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is SANUWAVE Health, Inc. Common Stock worth?
The market values SANUWAVE Health, Inc. Common Stock at about $77.5M (market capitalisation, as of Sep 23, 2026). Per share that is $4.71; our models calculate a fair value of $11.03 per share.
What do the bullish and bearish scenarios say about SNWV?
Our models span a range for SANUWAVE Health, Inc. Common Stock: cautious scenario $6.87, base $11.03, optimistic $17.33 per share (as of Sep 23, 2026, price $4.71). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SNWV?
SANUWAVE Health, Inc. Common Stock trades at a price-to-earnings ratio of 4.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $11.03 is built from several models across several years. Other multiples: P/B 47.9, P/S 1.7, EV/EBITDA 14.0.
How solid is the balance sheet of SANUWAVE Health, Inc. (SNWV)?
Balance-sheet figures for SANUWAVE Health, Inc. Common Stock (as of Sep 23, 2026): debt of 10.08 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is SNWV from its 52-week high?
SANUWAVE Health, Inc. Common Stock trades at $4.71, about 88% below its 52-week high of $40.82 and 18% above the low of $4.00 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $11.03 is for.
Which stocks are comparable to SANUWAVE Health, Inc. Common Stock?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SANUWAVE Health, Inc. Common Stock stock attractive at the current price?
The data as of Sep 23, 2026: price $4.71, calculated fair value $11.03 (+134%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SNWV calculated?
We run SANUWAVE Health, Inc. Common Stock through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $11.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. SANUWAVE Health, Inc. Common Stock currently trades 134 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SANUWAVE Health, Inc. (SNWV)?
The closing price on Sep 23, 2026 was $4.71. Our model-based fair value is $11.03, about +134% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SANUWAVE Health, Inc. Common Stock right now?
The price is below even our cautious bear case ($6.87). The market is more pessimistic than our downside scenario. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($6.87 to $17.33) leaves room in how you read the outcome.
Key figures of SANUWAVE Health, Inc. Common Stock
How large is the market capitalisation of SANUWAVE Health, Inc. (SNWV)?
The market capitalisation of SANUWAVE Health, Inc. Common Stock is $77.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SANUWAVE Health, Inc. (SNWV)?
The price-to-sales ratio of SANUWAVE Health, Inc. Common Stock is 1.31 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SANUWAVE Health, Inc. (SNWV)?
Earnings per share at SANUWAVE Health, Inc. Common Stock are $0.9600 (price ÷ EPS = P/E 4.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SANUWAVE Health, Inc. (SNWV)?
The net margin of SANUWAVE Health, Inc. Common Stock is 26.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of SANUWAVE Health, Inc. (SNWV)?
On an EBIT basis the return on assets of SANUWAVE Health, Inc. Common Stock is −18.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SANUWAVE Health, Inc. (SNWV)?
The operating margin of SANUWAVE Health, Inc. Common Stock is −11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SANUWAVE Health, Inc. (SNWV)?
Revenue at SANUWAVE Health, Inc. Common Stock is growing +3.1% versus a year earlier (3y avg +38.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does SANUWAVE Health, Inc. (SNWV) carry?
The net debt of SANUWAVE Health, Inc. Common Stock is $11.0M (fiscal year 2025, ≈ 5.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SANUWAVE Health, Inc. Common Stock in the live analysis
One click puts SANUWAVE Health, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026